Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue ACS Nano Année : 2016

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine

1 ISS - Istituto Superiore di Sanità = National Institute of Health
2 Trinity College Dublin
3 Hospital Germans Trias I Pujol
4 Department of Genetics, Cell- and Immunobiology
5 Universita di Torino
6 Università degli studi di Palermo - University of Palermo
7 Institute of Molecular Pathology and Immunology
8 Institute for Molecular and Cell Biology
9 Universidade do Porto = University of Porto
10 Hospital Clínic de Barcelona
11 Karolinska Institutet [Stockholm]
12 University of Oxford
13 Lek Pharmaceuticals d.d., a Sandoz Company
14 San Raffaele Scientific Institute
15 Ghent University Hospital
16 Bilkent University [Ankara]
17 University of Ljubljana
18 PhAN - Physiopathologie des Adaptations Nutritionnelles
19 University of Belgrade
20 University of Ioannina
21 HES-SO - University of Applied Sciences and Arts Northwestern Switzerland
22 UV - Universitat de València
23 ORT Braude College
24 Oslo University Hospital [Oslo]
25 University of Freiburg [Freiburg]
26 CNR - National Research Council of Italy | Consiglio Nazionale delle Ricerche
27 UZH - Universität Zürich [Zürich] = University of Zurich
28 Biologie Cellulaire et Cancer
29 Institut Curie [Paris]
30 Paracelsus Medical University
31 University of Salzburg
32 Helsingin yliopisto = Helsingfors universitet = University of Helsinki
33 Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200135 Oporto, Portugal
34 Univ Porto IPATIMUP, Inst Invest & Inovacao Saude i3S, P-4200135 Oporto, Portugal
35 Hospital Sta Cristina
36 Exosomics Siena SpA
37 National Institute of Chemistry
38 Institute for Transfusion Medicine
Marei Sammar
  • Fonction : Auteur
Guillaume van Niel

Résumé

Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and.Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.

Domaines

Immunologie

Dates et versions

hal-02640550 , version 1 (28-05-2020)

Identifiants

Citer

Stefano Fais, Lorraine O'Driscoll, Francesc E. Borras, Edit Buzás, Giovanni Camussi, et al.. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10 (4), pp.3886 - 3899. ⟨10.1021/acsnano.5b08015⟩. ⟨hal-02640550⟩
109 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More